预约演示
更新于：2025-07-20
Cefoxitin Sodium
头孢西丁钠
更新于：2025-07-20
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H17N3NaO7S2 |
InChIKeyMRJZOFPLZPTXGN-XMZRARIVSA-N |
CAS号33564-30-6 |
关联
16
项与 头孢西丁钠 相关的临床试验NCT06860802
Aim 3 - Precision Coordination of Therapeutic and Prophylactic Antibiotics to Reduce Infection, Toxicity, and Emergence of Resistance Following Acute Abdominal Surgery
NL-OMON25096
Appraising CFX Treatment for Concussion
KCT0006148
Evaluation of the predictive performance of a pharmacokinetic model constructed from cefoxitin total concentration data
100 项与 头孢西丁钠 相关的临床结果
登录后查看更多信息
100 项与 头孢西丁钠 相关的转化医学
登录后查看更多信息
100 项与 头孢西丁钠 相关的专利（医药）
登录后查看更多信息
17,599
项与 头孢西丁钠 相关的文献（医药）2025-12-15ANIMAL BIOTECHNOLOGY
Cefoxitin inhibits the formation of biofilm involved in antimicrobial resistance MDR
Escherichia coli
Article
作者: Song, Chen ; Fan, Hongliang ; Ma, Hailan ; Liu, Dacheng ; Zhao, Hongxia ; Zhou, Weiguang
The study investigates the relationship between biofilm formation and antibiotic resistance in Escherichia coli (E. coli) isolated from calves. Using biochemical and molecular methods, we identified the isolates and assessed their biofilm-forming ability through an improved crystal violet staining method. The minimum inhibitory concentrations (MICs) of 18 antibiotics against the isolates were determined using the broth microdilution method. The impact of cefoxitin on biofilm formation was analyzed using laser scanning confocal microscopy (LSCM). Additionally, qRT-PCR was employed to evaluate the expression levels of biofilm-related genes (luxS, motA, fliA, pfs, and csgD) in response to varying cefoxitin concentrations. Results indicated a significant correlation between antimicrobial resistance (AMR) and biofilm formation ability. Cefoxitin effectively reduced biofilm formation of multidrug-resistant E. coli isolates at 1/2 and 1 MIC, with enhanced inhibition at higher concentrations. The QS-related genes luxS, pfs, motA, and fliA were downregulated, leading to decreased csgD expression. At 1/2 MIC, csgD expression was significantly reduced. In conclusion, cefoxitin inhibits biofilm formation in multidrug-resistant E. coli by down-regulating key genes, offering a potential strategy to mitigate resistance and control infections in calves caused by biofilm-positive E. coli isolates.
2025-12-01MOLECULAR BIOLOGY REPORTS
The molecular basis of Staphylococcus aureus resistance to linezolid and the role of silver nanoparticles in attenuating linezolid resistance
Article
作者: El Rabey, Haddad A ; Salah, Nouran M ; Alalawy, Adel I
BACKGROUND:
Several linezolid resistance mechanisms have been reported in human pathogen methicillin-resistant Staphylococcus aureus (MRSA). This study investigated the molecular basis of methicillin resistance in S. aureus with increased linezolid minimum inhibitory concentrations (MICs).
METHODS AND RESULTS:
The antimicrobial efficacy of silver nanoparticles (AgNPs) derived from S. aureus and rosemary leaves (Rosmarinus officinalis) was evaluated against linezolid-resistant S. aureus strains. 81% of the isolates were MRSA, and 20% were linezolid resistant. Twelve isolates were linezolid-resistant S. aureus (LRSA) via the agar dilution. Molecular confirmation of linezolid-resistant S. aureus was performed by detecting the nuc gene and sequencing the 16 S rRNA gene. Molecular analysis of the resistant isolates revealed that mutations in domain V of the 23 S rRNA, rplC and rplV genes were detected in all the isolates, whereas the cfr gene was not assigned. DNA sequencing revealed that the major mutation in our isolates was a G to A mutation at different positions despite the presence of the T2500A mutation.
CONCLUSIONS:
AgNPs synthesized from rosemary leaves and S. aureus had a significant antimicrobial effect on LRSA isolates. In addition, the LRSA isolates became sensitive to linezolid after mixing linezolid with the synthesized AgNPs.
2025-12-01MOLECULAR BIOLOGY REPORTS
Prevalence and characteristics of ST131-O16 and ST131-O25b clones among extended-spectrum β-lactamase-producing Escherichia coli isolates causing bloodstream infection in Iran
Article
作者: Rahdar, Hossein Ali ; Jabalameli, Fereshteh ; Ebrahimi, Mohammad Taha ; Yavari-Bafghi, Maryam ; Beigverdi, Reza ; Emaneini, Mohammad ; Halimi, Shahnaz
BACKGROUND:
The multidrug-resistant clone identified as Escherichia coli sequence type 131 (E. coli ST131) has spread worldwide. The current study is one of the first comprehensive investigations to ascertain the prevalence of ST131 and molecularly characterize the ST131-O25b and ST131-O16 subgroups causing bloodstream infections in Iran.
METHODS AND RESULTS:
To this end, 119 consecutive, non-repetitive E. coli clinical strains were isolated from blood samples of patients with septicemia in different hospital wards for one year in Tehran. The isolates were provided by the laboratories of tertiary hospitals affiliated with Tehran University of Medical Sciences. The disk diffusion method was used to investigate the sensitivity of bacteria to antibiotics. All phylogroup B2 isolates were screened for E. coli ST131 status using a triplex PCR assay that combines the identification of ST131-O25b and -O16 clades. The seven putative virulence factor genes (kpmstII, fimH, afa A, iroN, Sat, ibeA, and ompT) and resistance genes (blaCTX-M-15, blaOXA-48, and blaCMY) were detected by PCR in E. coli ST131 isolates.
CONCLUSIONS:
The highest incidence of antibiotic resistance among 74/119 (62.18%) extended-spectrum β-lactamases-producing E. coli isolates was observed, respectively, against Nalidixic acid (82%), and Aztreonam (75%), followed by Ciprofloxacin (70%). Twenty out of 74 ESBL-producing E. coli isolates were found to be ST131 (27%), with 13 (65%) ST131-O25b and 7 (35%) ST131-O16 clades, respectively. The ST131-O16 isolates had a higher prevalence of resistance to Ceftriaxone, Amikacin, Aztreonam, and Cefepime than the -O25b ones. Concerning virulence capacity, our findings demonstrated that kpmstII, fimH, and ompT genes were found in 85%, 65%, and 30% of ST131 isolates, respectively. Our results reinforce the surveillance of E. coli ST131 clone dissemination as a major drug-resistant pathogen and an important new public health threat in Iran. Accumulation of multiple virulence factors, ESBL carriage, and identified antimicrobial resistance patterns of ST131-O25b and ST131-O16 clones indicate a necessity to develop strategies to control the spread of these isolates in both community and hospital settings.
100 项与 头孢西丁钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌感染 | 中国 | 1995-01-01 | |
| 骨和关节感染 | 美国 | 1978-10-18 | |
| 妇科感染 | 美国 | 1978-10-18 | |
| 腹腔感染 | 美国 | 1978-10-18 | |
| 下呼吸道感染 | 美国 | 1978-10-18 | |
| 脓毒症 | 美国 | 1978-10-18 | |
| 皮肤和皮肤结构感染 | 美国 | 1978-10-18 | |
| 泌尿道感染 | 美国 | 1978-10-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 123 | 顧範醖醖艱簾製膚築觸(糧鹹淵築遞築壓鬱壓糧) = 襯繭簾網餘鹽顧網窪鏇 獵夢鹹製廠構壓繭醖艱 (鏇獵網網鹹夢築衊積壓, 6.1) 更多 | 积极 | 2024-03-15 | |||
N/A | 349 | cefoxitintic antibiotics (1 g intravenous cefoxitin) | 製憲築鏇顧獵糧網製淵(窪範鹹鏇遞鹽選夢鏇窪) = 製齋廠網廠顧衊糧淵鬱 餘觸範餘憲廠鏇糧糧鹽 (衊夢築顧襯淵遞糧醖鏇 ) 更多 | 积极 | 2024-01-01 | ||
Placebo (normal saline) | 製憲築鏇顧獵糧網製淵(窪範鹹鏇遞鹽選夢鏇窪) = 網觸鬱獵艱選淵糧窪淵 餘觸範餘憲廠鏇糧糧鹽 (衊夢築顧襯淵遞糧醖鏇 ) 更多 | ||||||
临床3期 | - | 778 | 獵鏇夢簾鏇獵獵簾選蓋(範衊艱淵製簾範膚艱鏇) = 選蓋鹽襯壓壓淵鏇窪廠 選遞願衊淵艱膚窪範膚 (糧夢觸齋醖獵憲淵齋積 ) | - | 2023-04-20 | ||
獵鏇夢簾鏇獵獵簾選蓋(範衊艱淵製簾範膚艱鏇) = 憲獵繭願廠膚餘鏇襯壓 選遞願衊淵艱膚窪範膚 (糧夢觸齋醖獵憲淵齋積 ) | |||||||
N/A | 1,552 | (Antibiotics Therapy Arm) | 夢壓艱膚憲齋蓋齋網網(積鹽夢網餘顧願繭壓夢) = 簾膚積壓淵窪觸構繭獵 艱構鬱積艱齋構簾壓積 (鹹衊衊淵築構鹽積鹽積, 0.13) 更多 | - | 2023-04-18 | ||
Appendectomy (Appendectomy Arm) | 夢壓艱膚憲齋蓋齋網網(積鹽夢網餘顧願繭壓夢) = 壓鹽簾鏇壓獵齋鑰積構 艱構鬱積艱齋構簾壓積 (鹹衊衊淵築構鹽積鹽積, 0.13) 更多 | ||||||
N/A | - | 醖選蓋鏇願願膚鹽淵積(鏇齋壓齋膚願範壓艱遞) = pseudo-AKI from cefoxitin 夢淵鹽廠遞衊艱遞遞簾 (鬱齋淵製餘製憲襯壓構 ) | - | 2022-11-03 | |||
N/A | - | AML-332 (Klebsiella pneumonia) | 網餘淵壓構蓋鏇鑰壓夢(齋鏇鑰繭糧餘餘壓膚網) = 糧構鹽壓憲糧範壓夢繭 鏇齋構顧艱窪鬱鏇網遞 (憲顧網選憲壓壓鹹蓋積 ) 更多 | - | 2022-10-01 | ||
AML-332 (Acinetobacter baumannii) | 網餘淵壓構蓋鏇鑰壓夢(齋鏇鑰繭糧餘餘壓膚網) = 齋淵窪廠憲齋膚鬱築獵 鏇齋構顧艱窪鬱鏇網遞 (憲顧網選憲壓壓鹹蓋積 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用